Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (NY:BHC)

5.795 -0.315 (-5.16%)
Streaming Delayed Price Updated: 12:09 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags
S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day. 
Via Benzinga
Topics Bankruptcy Stocks
Exposures Financial Legal US Equities
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb. 
Via Benzinga
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
Via ACCESSWIRE
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
Via ACCESSWIRE
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Bausch Health Announces Second Quarter 2024 Results
Via ACCESSWIRE
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off. 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns. 
Via Investor's Business Daily
Bank Of Canada Cuts Rates Again As Inflation, Labor Market Cool: Canadian Stocks Rebound, Loonie Strengthens
Bank of Canada cuts key policy rate by 25 basis points to 4.25% and suggests further cuts if inflation continues to ease. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Bausch Health Responds to Market Rumors
Via ACCESSWIRE
Bausch Health Welcomes Two New Members to the Executive Leadership Team
Via ACCESSWIRE
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
Bausch Health reports Q2 2024 GAAP EPS of $0.03, missing the consensus of $0.28. Revenue hits $2.403 billion, up 11% YoY. Piper Sandler downgrades BHC to Underweight with a price target of $3, citing... 
Via Benzinga
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy
Although Bausch Health has denied rumors that it’s on the cusp of bankruptcy, BHC stock is nevertheless suffering from skepticism. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Why Bausch health Shares Are Falling Today
Bausch Health Companies Inc. (NYSE: BHC) is experiencing a sharp decline in its stock price Wednesday. The drop was triggered by a report suggesting the company is negotiating a potential prepackaged... 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Stocks Plummet After Tech Earnings, Manufacturing Data
The Dow Jones Industrial Average is down triple digits, while the S&P 500 Index eyes its worst daily percentage drop since September 2023. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Via ACCESSWIRE
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Via ACCESSWIRE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Via ACCESSWIRE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Via ACCESSWIRE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Via ACCESSWIRE
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Via ACCESSWIRE
Why Bausch Health Companies Stock Dived by More Than 7% Today
A large red number on the bottom line attracted the wrong kind of investor attention for the company. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.